Clinical and genetic relationships in patients with chronic hepatitis C


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To identify clinical and genetic relationships and to determine predictors for a response to standard dual therapy in patients with chronic hepatitis C (CHC). Subjects and methods. A Moscow cohort of 70 СНС patients aged 18 to 70 years was examined and divided into 2 groups: 1) 37 patients who responded to standard dual (IFN-α + ribavirin) antiviral therapy (AVT); 2) 33 patients who failed to respond to the same AVT. All the patients underwent genotyping of polymorphic loci in the interleukin 28B (IL-28B) gene and determination of С/С, С/Т and Т/Т (rs12979860), G/G, T/G and Т/Т (rs8099917) genotypes, as well as a hepatic C virus (HCV) genotype was identified. Results. IL-28B C/C (rs12979860) and Т/Т (rs8099917) genotypes were significantly more frequently recorded in Group 1. An analysis of the relation of the genotypes of patients at different IL-28B loci and the efficiency of treatment revealed that the patients with CHC caused by genotype 1 HCV were more commonly found to have the T/T genotype at the rs12979860 loci in 36.4% of cases versus 3.9% in non-genotype 1 HCV patients (p < 0.05). In Group 2, the C/T genotype was identified in both genotype 1 HCV and non-genotype 1 HCV in 66.7% of cases. Analysis of IL28B rs80999927 genotypes revealed no significant differences in their proportion in both HCV genotypes and in relation to a therapeutic response. Conclusion. The data obtained from the analysis of the Moscow cohort of CHC patients suggest that IL-28B C/C (rs12979860) and TT (rs8099917) genotypes are favorable prognostic factors of an AVT response

Full Text

Restricted Access

About the authors

V. V Makashova

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: veramakashova@yandex.ru

S. D Kuznetsov

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: kuznetsov-crie@yandex.ru

A. V Tutelyan

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: bio-tav@yandex.ru

S. V Shabalina

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: nex@pcr.ru

References

  1. Santantonio T., Sinisi E., Guastadisegni A., Casalino C., Mazzola M., Gentile A., Leandro G., Pastore G. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis. 2003; 35(2): 104-113.
  2. Сюткин В.Е. Новые возможности увеличения эффективности противовирусной терапии больных ХГС. Инфекционные болезни 2009; 2(7): 55-59.
  3. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958-965.
  4. Кузнецов С.Д., Макашова В.В., Тутельян А.В., Шабалина С.В. Взаимосвязь генетических факторов вируса и больного при хроническом гепатите С. Инфекционные болезни 2015; 3(17): 30-36.
  5. Тихонова Н.Ю., Бурневич Э.З. Новые возможности прогнозирования ответа на противовирусную терапию хронического гепатита С. Фарматека 2012; 2(235): 32-35.
  6. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461(7262): 399-401.
  7. Kempurai D., Donelan J., Frydas S., Iezzi T., Conti F., Boucher W., Papadopoulou N.G., Madhappan B., Letourneau L., Cao J., Sabatino G., Meneghini F., Stellin L., Verna N., Riccioni G., Theoharides T.C. Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities. Int. J. Immunopathol. Pharmacol. 2004; 17(2): 103-106.
  8. Stattermayer A.F., Stauber R., Hofer H., Rutter K., Beinhardt S., Scherzer T.M., Zinober K., Datz C., Maieron A., Dulic-Lakovic E., Kessler H.H., Steindl-Munda P., Strasser M., Krall C., Ferenci P. Impact of IL 28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 2011; 9(4): 344-350.
  9. O'Brien T.R., Everhart I.E., Morgan T.R., Lok A.S., Chung R.T., Shao Y., Shiffman M.L., Dotrang M., Sninsky J.J., Bonkovsky H.L., Pfeiffer R.M., HALT-C Trial Group. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One 2011; 6(7): e20904.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies